Promising Clinical Trial Results for Rolvedon Injection
Assertio Holdings, Inc. has made exciting strides in the pharmaceutical sector with its recent announcement regarding Rolvedon (eflapegrastim-xnst) injection. This innovative treatment solution was tested in a clinical trial that focused on same-day dosing for patients receiving chemotherapy, particularly those battling early stage breast cancer (ESBC). The significance of these results was highlighted at a major breast cancer symposium, showcasing the company's dedication to enhancing patient care.
Details of the Clinical Study
This clinical trial was an open-label, single-arm study that involved participants receiving Rolvedon just 30 minutes following their chemotherapy treatment. Conducted across 13 different sites within the United States, the study showcased impressive outcomes. Notably, patients using Rolvedon experienced an average of only 1.8 days until their neutrophil counts recovered and reported a minimal febrile neutropenia rate of just 2%. Importantly, there were no significant safety concerns, as none of the participants required hospitalization or additional medical intervention due to complications.
Statements from Company Leadership
Brendan O’Grady, CEO of Assertio Therapeutics, expressed his satisfaction with the results from the trial, stating, "We are pleased with the expected, positive results from the Rolvedon same day dosing trial." He further emphasized the company's commitment to improving patient lives through effective treatment options. Dr. Howard Franklin, Senior Vice President of Medical Affairs, also shared his thoughts, praising the trial's safety and efficacy results. He mentioned, "The excellent safety and efficacy profile of Rolvedon in this trial is very encouraging, providing clinical data indicating that same day dosing outcomes are safe and effective for this unique molecule. This directly supports our aim of enhancing patient quality of life.”
About Assertio Holdings, Inc.
Assertio stands out as a commercial pharmaceutical company dedicated to providing differentiated products that fulfill patient needs. The company has meticulously built its commercial portfolio through strategic acquisitions and licensing of approved products. Assertio's marketing approach blends direct sales efforts with non-personal promotion, alongside effective payor contracting to ensure broad market access and distribution capabilities.
Learning More About Assertio
Potential investors and interested parties are encouraged to explore the company's offerings in detail. Assertio’s strategic initiatives and comprehensive product portfolio highlight its focus on patient-centered strategies within the pharmaceutical landscape.
Insights into Future Directions
The results from the Rolvedon clinical trial exemplify Assertio's commitment to innovation and patient care. With Rolvedon displaying such promising efficacy in improving patient outcomes, it opens doors for further research and development within the field of cancer treatments. Patients and healthcare providers will appreciate the advancements made in administering chemotherapy as effective solutions continue to evolve.
Frequently Asked Questions
What is Rolvedon?
Rolvedon is an injection treatment designed for patients undergoing chemotherapy, specifically targeting early stage breast cancer.
What were the main results of the clinical trial?
The trial showed a neutrophil count recovery in an average of 1.8 days and a low febrile neutropenia rate of 2%, with no hospitalizations required.
Who oversees Assertio Holdings?
Assertio is led by Brendan O’Grady, the CEO, who emphasizes the company’s mission to enhance patient care through effective oncology treatments.
Where was the clinical trial conducted?
The clinical trial took place across 13 sites in the United States, ensuring a comprehensive study design.
How can I find more information about Assertio?
Further details about Assertio Holdings and its products can be found on their official website at www.assertiotx.com.
